Skip to main content

Table 1 Associations of clinical variables with OS in BRCA (total N = 979)

From: Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy

   N % HR (95%CI) P
Radiotherapya No 421 43.00 1.000  
  Yes 558 57.00 0.520(0.340, 0.795) 0.003
Chemotherapya No 140 14.42 1.000  
  Yes 831 85.58 0.382(0.230, 0.635) < 0.001
Agea < 60 526 53.78 1.000  
  ≥ 60 452 46.22 2.005(1.339, 3.004) < 0.001
Race White 680 74.97 1.000  
  Others 227 25.03 1.336(0.844, 2.116) 0.217
History of cancer No 915 93.56 1.000  
  Yes 63 6.44 1.621(0.746,3.521) 0.223
Surgery typea Mastectomy 465 50.05 1.000  
  Lumpectomy 235 25.30 0.928(0.544, 1.581) 0.782
  Other 229 24.65 0.596(0.359, 0.989) 0.045
Margin statusa Negative 841 89.09 1.000  
  Positive/close 103 10.91 1.750(1.063, 2.882) 0.028
Histology IDC 697 71.20 1.000  
  ILC 191 19.51 0.950(0.551, 1.639) 0.854
  Other 91 9.30 1.614(0.898, 2.900) 0.140
ER status Negative 215 22.95 1.000  
  Positive 722 77.05 1.118(0.585, 2.137) 0.736
PR statusa Negative 308 32.98 1.000  
  Positive 626 67.02 0.563(0.375, 0.846) 0.006
HER2 Negative 496 60.41 1.000  
  Positive 142 17.30 1.172(0.682, 2.013) 0.567
  Indeterminate 183 22.29 0.904(0.572, 1.429) 0.667
Menopausal status Pre/peri 286 30.75 1.000  
  Post 644 69.25 1.487(0.868,2.547) 0.148
T Stage T1/T2 822 84.22 1.000  
  T3/T4 154 15.78 0.971(0.565, 1.668) 0.914
N Stagea N0 466 48.49 1.000  
  N1/N2/N3 495 51.51 1.851(1.096, 3.127) 0.021
M Stagea M0 961 98.16 1.000  
  M1 18 1.84 1.998(1.031, 3.869) 0.040
Pathological stagea I/II 717 74.84 1.000  
  III/IV 241 25.16 2.147(1.269, 3.635) 0.004
  1. IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; TNM, tumor-node-metastasis stage
  2. aClinical variables that were left after fast backward multivariate COX regression